ArticleJournal of the American Heart Association2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction.ESC heart failure · 2025Pooled it
- Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.European journal of heart failure · 2025Trial
- The Impact of Risk Factors and Comorbidities on Heart Failure in the Aging Population.International journal of molecular sciences · 2026Review
- Baseline Chronic Obstructive Pulmonary Disease Identifies a High-Risk Cardiopulmonary Phenotype in Patients with Heart Failure Undergoing SGLT2 Inhibitor Therapy.Diagnostics (Basel, Switzerland) · 2026Article
- Challenges in the Early Diagnosis, Screening and Management of Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2026Review
- Association between β-blocker use and outcomes in patients with heart failure and chronic obstructive pulmonary disease: a retrospective cohort study.Scientific reports · 2026Article
- Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated.Heart failure reviews · 2025Review
- Angiotensin receptor-neprilysin inhibitor treatment in people with chronic obstructive pulmonary disease and heart failure.Communications medicine · 2025Article
- The Complex Relationship Between Heart Failure and Chronic Obstructive Pulmonary Disease: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Features of Heart Failure with Preserved Ejection Fraction in Patients with Chronic Obstructive Pulmonary Disease and Systemic Sclerosis-Associated Interstitial Lung Diseases.Journal of personalized medicine · 2025Article
- Heart failure with supranormal ejection fraction: clinical characteristics and outcomes compared to mildly reduced and preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Phenotyping patients with chronic obstructive pulmonary disease and heart failure.ESC heart failure · 2025Article
- Prognostic implication of outpatient loop diuretic dose intensification trajectories in patients with chronic heart failure.International journal of cardiology. Heart & vasculature · 2025Article
- A noninvasive strategy for multi-disease diagnosis via multi-sensor platform: integrative analysis of five years of exhaled breath-based diagnostics for seven diseases.Frontiers in bioengineering and biotechnology · 2025Article
- Characteristics, Treatment, and Prognosis of Heart Failure Patients with Chronic Obstructive Pulmonary Disease in the Colombian Heart Failure Registry (RECOLFACA).Journal of cardiovascular development and disease · 2024Article
- Heart failure with preserved ejection fraction.Nature reviews. Disease primers · 2024Review
- Advanced Heart Failure Characteristics and Outcomes in Women and Men.Journal of the American Heart Association · 2024Article
- Iron deficiency and supplementation in heart failure.Nature reviews. Cardiology · 2024Review
- Pulmonary hypertension across the spectrum of left heart and lung disease.European journal of heart failure · 2024Observational
- Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty.International journal of heart failure · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 5 countries.
Funding
Abstract
Background Little is known about the impact of chronic obstructive pulmonary disease (COPD) in patients with heart failure with preserved ejection fraction (HFpEF). Methods and Results We examined outcomes in patients with heart failure with preserved ejection fraction, according to COPD status, in the PARAGON-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in Heart Failure With Preserved Ejection Fraction) trial. The primary outcome was a composite of first and recurrent hospitalizations for heart failure and cardiovascular death. Of 4791 patients, 670 (14%) had COPD. Patients with COPD were more likely to be men (58% versus 47%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.